Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2025)

Cytek Biosciences' Current Deferred Revenue history spans 6 years, with the latest figure at $28.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 11.82% year-over-year to $28.5 million; the TTM value through Dec 2025 reached $28.5 million, up 11.82%, while the annual FY2025 figure was $28.5 million, 11.82% up from the prior year.
  • Current Deferred Revenue reached $28.5 million in Q4 2025 per CTKB's latest filing, down from $28.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $29.6 million in Q2 2023 to a low of $4.7 million in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $20.3 million, with a median of $23.0 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: crashed 46.23% in 2021, then soared 241.0% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $7.1 million in 2021, then surged by 83.39% to $13.0 million in 2022, then surged by 74.77% to $22.7 million in 2023, then grew by 12.32% to $25.5 million in 2024, then increased by 11.82% to $28.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Current Deferred Revenue are $28.5 million (Q4 2025), $28.7 million (Q3 2025), and $28.1 million (Q2 2025).